Development of Doxorubicin-Loaded Nanostructured Lipid Carriers: Preparation, Characterization, and In Vitro Evaluation on MCF-7 Cell Line

被引：12
作者：
Abdolahpour S. [1 ]
Mahdieh N. [2 ]
Jamali Z. [1 ]
Akbarzadeh A. [3 ]
Toliyat T. [4 ]
Paknejad M. [1 ]
机构：
[1] Department of Medical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran
[2] Shahid Rajaei Cardiovascular, Medical and Research Center, Tehran University of Medical Sciences, Tehran
[3] Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz
[4] Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran
来源：
BioNanoScience | 2017年 / 7卷 / 1期
关键词：
Cytotoxicity; Doxorubicin; MCF-7; Nanostructured lipid carrier;
D O I：
10.1007/s12668-016-0391-x
中图分类号：
学科分类号：
摘要：
Nanostructured lipid carriers (NLC) are produced using a blend of solid and liquid lipids; this blend is solid at room temperature. NLC is a second generation of lipid nanoparticles, which offer the advantage of improved drug-loading capability and release properties. The purpose of this study was to find the optimized proportion of liquid and solid lipids for production of doxorubicin (Dox)-loaded NLC (Dox-NLC) to decrease the cytotoxicity of Dox. Dox-NLC was prepared by the solvent emulsification/evaporation method using stearic acid (SA) and oleic acid (OA) as the solid lipid and liquid lipid, respectively. Poloxamer 188 and lecithin were used to stabilize NLC dispersion. The physicochemical characteristic and cytotoxicity of Dox-NLC were evaluated. The NLC prepared by 0.6% of stearic acid and 0.4% of oleic acid, showed optimum results with particle size of 134.0 ± 2.3 nm, zeta potential of −19.0 ± 3.9 mV, drug-loading efficiency of 9.5%, and entrapment efficiency of 75%. The drug loading after freeze drying and also after 60 days storage at 4 °C did not change. In vitro drug release study showed that Dox was released from the NLC in a slow but time-dependent behavior. The cytotoxicity of Dox-NLC on MCF-7 cell line was increased compared with the Dox solution. These results suggested that the Dox-NLC produced by this method could be utilized as a sustained release drug carrier system for improving the effectiveness of chemotherapy. © 2017, Springer Science+Business Media New York.
引用
收藏
页码：32 / 39
页数：7
相关论文
共 37 条
  • [1] Thorn C.F., Oshiro C., Marsh S., Hernandez-Boussard T., McLeod H., Klein T.E., Et al., Doxorubicin pathways: pharmacodynamics and adverse effects, Pharmacogenetics and genomics, 21, pp. 440-446, (2011)
  • [2] Singla S., Kumar N.R., Kaur J., In vivo studies on the protective effect of Propolis on doxorubicin-induced toxicity in liver of male rats, Toxicology International, 21, pp. 191-195, (2014)
  • [3] Bajelan E., Haeri A., Vali A.M., Ostad S.N., Dadashzadeh S., Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance, Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne des Sciences Pharmaceutiques, 15, pp. 568-582, (2012)
  • [4] Primeau A.J., Rendon A., Hedley D., Lilge L., Tannock I.F., The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors, Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 11, pp. 8782-8788, (2005)
  • [5] Pardeike J., Hommoss A., Muller R.H., Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, International Journal of Pharmaceutics, 366, pp. 170-184, (2009)
  • [6] Anari E., Akbarzadeh A., Zarghami N., Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line, Artificial Cells, Nanomedicine, and Biotechnology, 44, pp. 1410-1416, (2016)
  • [7] Pradhan M., Singh D., Singh M.R., Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches, Journal of Controlled Release: Official Journal of the Controlled Release Society, 170, pp. 380-395, (2013)
  • [8] Gohla S.H., Dingler A., Scaling up feasibility of the production of solid lipid nanoparticles (SLN), Die Pharmazie, 56, pp. 61-63, (2001)
  • [9] Selvamuthukumar S., Velmurugan R., Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy, Lipids in Health and Disease, 11, (2012)
  • [10] Naseri N., Valizadeh H., Zakeri-Milani P., Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application, Advanced Pharmaceutical Bulletin, 5, pp. 305-313, (2015)
1234